When microbes evolve biological mechanisms that can protect them from elimination by antimicrobial, the danger of antimicrobial resistance (AMR) is visible. AMR are drug-resistant pathogens whose spread is a growing public health concern in many countries. The growth of resistant bacteria usually happens due to overuse of antibiotics, or due to their use being different from what has been prescribed. This renders antibiotics less effective or ineffective. It is believed that by 2050, AMR infections may cause 10 million deaths annually. Increase in hospitalizations and increasing use of antibiotics in COVID-19 treatment are expected to further exacerbate AMR. Hence, the market for antibiotic resistance research and medicines useful for treatment is expected accelerate in the near future.
Tuberculosis (TB) is one of the most dangerous infectious diseases from a single infectious agent and its virus has developed significant antibiotic resistance in the modern times. Multidrug-resistant TB (MDR-TB) is considered a global public health emergency by the World Health Organization. According to 2017 estimates, 465,000 cases of TB were estimated worldwide. 38% people were eligible for MDR/Rifampicin-resistant (RR)-TB. 57% of MDR/RR-TB cases received successful treatment. Mylan has also secured approval from Drugs Controller General of India (DCGI) for Pretomanid, which is useful for treatment for highly drug-resistant forms of tuberculosis. Johnson & Johnson has been in the business of developing and responsibly deploying innovative technologies and treatments to combat the growing threat of AMR on multiple fronts.
Request a sample Copy@
https://www.absolutemarketsinsights.com/request_sample.php?id=876
The major factor driving the growth of global antibiotic resistance market is the growing prevalence of hospital-acquired infections. Antibiotic resistant bacteria can spread from person to person in the community. Implementing precautionary infection control procedures can minimize spread of such bacteria in hospitals. From person to person, usually this infection spreads from contact with either contaminated hands of hospital staff, or contaminated surfaces such as door handles, over-bed tables and call bells. Sometimes it also spreads due to contact with contaminated equipment that includes stethoscopes and blood pressure cuffs.
Strategic investments coupled with favorable initiatives by regulatory authorities showcases significant opportunities for the growth of global antibiotic resistance market over the period of next eight years. The Food and Drug Administration (FDA) of the United States of America (USA) and the Centers for Disease Control (CDC) in USA have launched several initiatives to help address antibiotic resistance. FDA is also encouraging new research into effective diagnostic tests, antibiotic regimens, and vaccines. Under qualified infectious disease product (QIDP) program, which is meant to encourage antibiotic development, FDA has also approved new and innovative antibiotics for resistant infections. Such antibiotics include Arikayce (amikacin liposome inhalation suspension), Baxdela (delafloxacin), Nuzyra (omadacycline), Pretomanid, Recarbrio (cilastatin, imipenem, & relebactam), Xerava (eravacycline), and Xepi (ozenoxacin).
The different variants of the coronoavirus has had severe impact on patients. Increased dosage of antibiotics are being prescribed to COVID patients who developed co-infections (bacterial with coronavirus). Increased investments into research and development initiatives towards adequate treatment of the same is anticipated to propel the growth of global antibiotic resistance market over the forecast period.
Enquiry Before Buying@
https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=876
Key Findings of the Report:
- The global antibiotic resistance market was valued at US$ 8417.36 Mn in 2020 growing at a CAGR of 4% over the forecast period (2021 – 2029).
- The carbapenem-resistant enterobacteriaceae (CRE) category in the global antibiotic resistance market held the larger market share in 2020. Carbapenem-resistant enterobacteriaceae (CRE) are a family of bacteria that are very difficult to treat due to their highly resistant nature towards antibiotics. They have a reputation of adapting to different types of antibiotic treatments and develop resistance towards them.
- The complicated urinary tract infections (cUTI) category in the global antibiotic resistance market held the larger share in 2020. Urinary tract infections (UTIs) are considered to be one of the most common types of infections. According to studies, at least one in two women and one in 10 men experience UTI in their life period.
- Antifolates segment occupied the largest market share in the global antibiotic resistance market in 2020. Antifolate drugs are helpful in the treatment of communicable and infectious diseases such as malaria. Many bacteria and viruses that have developed antibiotic resistance spread diseases similar to malaria, such as dengue and other mosquito-borne diseases.
- In 2020, North America dominated the global antibiotic resistance market. Availability of advanced medical sector, increasing prevalence of infectious diseases, presence of major market players, numerous drug launches in the market, and rising growth in the pharmaceutical sector amongst other factors have contributed towards the region’s highest share. Infectious Diseases Society of America (IDSA) has approved the use of many new drugs that are expected to offer successful treatment against bacteria and viruses that have developed antibiotic resistance.
- Some of the major players operating in the global antibiotic resistance market are Allergan Pharma Co., GlaxoSmithKline PLC., Johnson & Johnson Services Inc., MELINTA THERAPEUTICS - THE ANTIBIOTICS COMPANY, Merck & Co. Inc., Mylan N.V., Nabriva Therapeutics PLC, Otsuka Novel Products GmbH, Pfizer Inc., and Sandoz AG amongst others.
Request for Customization@
https://www.absolutemarketsinsights.com/request_for_customization.php?id=876
Global Antibiotic Resistance Market:
- By Resistant Bacteria Type
- Pseudomonas Aeruginosa
- Clostridioides difficile (C. difficile)
- Carbapenem-resistant Enterobacteriaceae (CRE)
- Streptococcus pneumoniae (S. pneumoniae)
- Acinetobacter
- Vancomycin-resistant Enterococci (VRE)
- Mycobacterium Tuberculosis (TB)
- Neisseria gonorrhoeae (N. gonorrhoeae)
- Others
- By Disease Indication
- Complicated Urinary Tract Infections (cUTI)
- Complicated Intra-Abdominal Infections (cIAI)
- Community-Acquired Bacterial Pneumonia (CABP)
- Acute Skin and Skin Structure Infections (ABSSSI)
- Multidrug-Resistant (MDR) and Pulmonary Extensively Drug Resistant (XDR) Tuberculosis (TB) (MDR-TB and XDR-TB)
- Sepsis
- Clostridium Difficile (C. difficile) Infections
- Others
- By Drug Class
- Antimycobacterials
- Fluoroquinolones
- Oxazolidinones
- Tetracyclines
- Penicillins
- Antifolates
- Combination Treatment
- Others
- By Route of Administration
- Oral
- Topical
- Intramuscular
- Intravenous (IV)
- By End Use
- Home Care
- Healthcare Facilities
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
For More Information Click@ https://www.absolutemarketsinsights.com/reports/Antibiotic-Resistance-Market-2021---2029-876
About Us:
Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.
Contact Us:
Company: Absolute Markets Insights
Email id: [email protected]
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna
The Work Lab,Model Colony, Shivajinagar, Pune, MH, 411016
Website: https://www.absolutemarketsinsights.com/